Expertise in
19
conditions

Dr. Philip L. Mccarthy

Hematology
Roswell Park Cancer Institute Corp
Elm And Carlton Sts, 
Buffalo, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
19
conditions
Roswell Park Cancer Institute Corp
Elm And Carlton Sts, 
Buffalo, NY 

Overview

Philip Mccarthy is a Hematologist practicing medicine in Buffalo, New York.

Dr. Mccarthy is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 185 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Roswell Park Cancer Institute Corp
Elm And Carlton Sts, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Other, Drug, Procedure
Study Drugs: Lenalidomide, Melphalan
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2026
Intervention Type: Drug, Biological
Study Drugs: TAK-007, Chemotherapy Agents
Study Phase: Phase 2
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss
A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss
Enrollment Status: Completed
Publish Date: March 13, 2024
Intervention Type: Biological
Study Drug: Denosumab
Study Phase: Phase 2
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: January 31, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

185 Total Publications

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2026
Similar Doctors
Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Roswell Park Comprehensive Cancer Center

665 Elm St, 
Buffalo, NY 
 (0.3 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Eunice Wang is a Hematologist practicing medicine in Buffalo, New York. Dr. Wang is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Vitrectomy.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Roswell Park Cancer Institute Corp

Elm And Carlton Sts, 
Buffalo, NY 
 (0.1 miles away)
716-845-7110
Languages Spoken:
English
See accepted insurances

Elizabeth Griffiths is a Hematologist practicing medicine in Buffalo, New York. Dr. Griffiths is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration.

Expertise in
6
conditions
Dr. Matthew J. Barth
Hematology | Oncology
Expertise in
6
conditions
Dr. Matthew J. Barth
Hematology | Oncology
Referral may be required

Office

219 Bryant St, 
Buffalo, NY 
 (1.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Matthew Barth is a Hematologist and an Oncologist practicing medicine in Buffalo, New York. Dr. Barth is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Burkitt Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Primary Mediastinal B-Cell Lymphoma (PMBCL).

Frequently Asked Questions about Dr. Philip L. Mccarthy

How do I make an appointment with Dr. Philip L. Mccarthy?

You can book an appointment with Dr. Philip L. Mccarthy by calling their office at 716-845-1444. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Philip L. Mccarthy a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Philip L. Mccarthy is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Philip L. Mccarthy specialize in?

While Dr. Philip L. Mccarthy is a Hematology, they have specific expertise in Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Philip L. Mccarthy participate in research or clinical trials?

Yes. Dr. Philip L. Mccarthy has published 185 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Philip L. Mccarthy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Philip L. Mccarthy accept my insurance?

Dr. Philip L. Mccarthy accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 716-845-1444 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccarthy's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 11 Advanced Conditions
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile